A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

• ClinicalTrials.gov Identifier: NCT02078102
• Recruitment Status: Recruiting
• First Posted: March 5, 2014
• Last Update Posted: May 1, 2019
• Sponsor: Sherif S. Farag
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): Sherif S. Farag, Indiana University School of Medicine

Study Description

Brief Summary:

The trial is an open label Simon optimal two-stage Phase II trial of fixed doses of oral meloxicam and subcutaneous filgrastim to assess the safety and efficacy in mobilizing autologous peripheral blood stem cells (PBSC) from multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) patients planning to undergo high-dose chemotherapy with stem cell support. Clinical data regarding the cellular composition and function of the graft mobilized by this combination will be obtained.

Condition or disease	Intervention/treatment	Phase
Multiple Myeloma; Non-Hodgkin's Lymphoma	Drug: Meloxicam; Drug: Filgrastim	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 32 participants
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Trial of Prostaglandin E2 Inhibition, Using Meloxicam, Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
• Actual Study Start Date: March 11, 2014
• Estimated Primary Completion Date: November 1, 2019
• Estimated Study Completion Date: January 1, 2020

Arms and Interventions

Arm

Intervention/treatment

Treatment; Meloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis. 15 mg tablets of Meloxicam will be taken orally for 5 consecutive days. 10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection.

Drug: Meloxicam; 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.; Other Name: Mobic; Drug: Filgrastim; Filgrastim will be subcutaneously injected in one or two sites at home.; Other Name: Neupogen

Outcome Measures

Primary Outcome Measures :

1. Number of patients who mobilize and collect at least half of the total target CD34+ cell dose in the first apheresis [ Time Frame: 4 years ]

   The objective of this study is to investigate whether meloxicam and filgrastim can result in a 20% increase in the proportion of patients who mobilize and collect at least half of the total target CD34+ cell dose in the first apheresis. As the total target CD34 dose varies with disease, the primary objective will be as follows according to disease:

   • Multiple myeloma patients: Investigate if meloxicam and filgrastim can result in an increase in the proportion of patients who mobilize and collect ≥5x106 CD34 cells/kg in the first day's apheresis, from a historical 40% to at least 60%.

   • Non-Hodgkin's lymphoma patients: Investigate if meloxicam and filgrastim can result in an increase in the proportion of patients who mobilize and collect ≥2.5x106 CD34 cells/kg in the first day's apheresis, from a historical 50% to at least 70%.

Secondary Outcome Measures :

1. Toxicity Profile of Meloxicam and Filgrastim [ Time Frame: 4 years ]
   Describe the toxicity profile of the combination of Meloxicam and Filgrastim
2. Graft Composition of Peripheral Blood Stem Cell Collection [ Time Frame: 4 years ]
   Describe the graft composition of PBSC collected using Meloxicam and Filgrastim including hematopoietic and immune cell subsets.
3. Engraftment Kinetics of Meloxicam and Filgrastim [ Time Frame: 4 years ]
   Describe the engraftment kinetics of Meloxicam and Filgrastim mobilized PBSC in MM and NHL patients undergoing myeloablative autologous PBSC transplantation

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study:

1. Has provided written informed consent prior to completing any study procedures.

2. Patients must have a previously documented histologic diagnosis of multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL), and be eligible to undergo autologous PBSC transplantation on institutional protocols.

   1. Multiple myeloma should be in first or second partial response or better, as defined by International Myeloma Working Group criteria.50

   2. Non-Hodgkin's lymphoma must be in either first or second partial response or better and have any one of the following histologies:

      • Diffuse large B cell lymphoma
      • Transformed lymphoma
      • Mantle cell lymphoma
      • Follicular lymphoma (any grade)
      • Peripheral T cell lymphoma
3. Age ≥18 to ≤75 years at time of consent.
4. Karnofsky performance status of at least 70%.

5. Adequate organ function defined as:

   1. Left ventricular ejection fraction ≥45%
   2. Corrected DLCO ≥50%
   3. Serum bilirubin, AST (aspartate aminotransferase) and ALT(alanine aminotransferase) ≤ twice the upper limit of normal
   4. Serum creatinine ≤ 2.0 mg/dl
   5. Urine M-protein ≤1 g/24 hours (MM patients only)
6. No prior attempt at mobilizing PBSC.
7. Patients must be at least 4 weeks from last cytotoxic chemotherapy (including alkylating, anthracyclines, epipodophylatoxins, and platinum drugs), or immunomodulatory drugs (including lenalidomide or pomalidomide, or related derivatives) at time of treatment on this protocol.
8. Patients must be at least 2 weeks from last treatment with a proteasome inhibitor (e.g., bortezomib, carfilzomib) at time of treatment on this protocol.
9. Patients must be negative for HIV.

10. Women of childbearing potential must have a negative pregnancy test (urine or serum) and must not be lactating at the time of informed consent.

    1. Women and men must use adequate birth control while taking part in this study (such as a condom or diaphragm with contraceptive cream/jelly, birth control pills, Norplant, abstinence (no sexual intercourse) or surgical sterilization.

Exclusion Criteria:

Exclude a patient if any of the following conditions are observed:

1. Patients must not have received radiation therapy within the past 4 weeks, and not to more than 20% of hematopoiesis forming bones (spine, pelvis and proximal long bones).
2. Patients must not have active central nervous system involvement.
3. Patients must not have a prior autologous, syngeneic or allogeneic hematopoietic stem cell transplant.
4. Patients must not have received prior bone seeking radionuclides.
5. Patients must not have received myeloid growth factors within 2 weeks before mobilization attempt on this study.
6. Patients must not have taken nonsteroidal antiinflammatory drugs (NSAID) in the past 14 days before treatment on this protocol.

7. Patients must not have nor had active or recent peptic ulcer disease within the past 6 months.

   a) Patients with active significant symptoms of dyspepsia will be excluded.

8. Patients with a history of asthma will be excluded because of the potential for NSAID to precipitate asthma in these patients.

Contacts and Locations

Contacts

Contact: Carol Huntley, RN; 317-274-3782; chuntley@iu.edu

Locations

United States, Indiana

Indiana University Melvin and Bren Simon Cancer Center; Recruiting

Indianapolis, Indiana, United States, 46202

Contact: Carol Huntley, RN 317-274-3782 chuntley@iu.edu

Contact: Sherif Farag, MBBS, PhD 317-274-0843 ssfarag@iupui.edu

Principal Investigator: Sherif Farag, MBBS, PhD

Sponsors and Collaborators

Sherif S. Farag

National Cancer Institute (NCI)

Investigators

• Principal Investigator: Sherif Farag, M.D., Ph.D.; Indiana University

More Information

• Responsible Party: Sherif S. Farag, Principal Investigator, Indiana University School of Medicine
• ClinicalTrials.gov Identifier: NCT02078102 History of Changes
• Other Study ID Numbers: IUCRO-0419; CA182947 ( Other Grant/Funding Number: NCI ); 1312925163 ( Other Identifier: Indiana University IRB )
• First Posted: March 5, 2014
• Last Update Posted: May 1, 2019
• Last Verified: April 2019

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Lymphoma; Multiple Myeloma; Neoplasms, Plasma Cell; Lymphoma, Non-Hodgkin; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemorrhagic Disorders; Meloxicam; Lenograstim; Adjuvants, Immunologic; Immunologic Factors; Physiological Effects of Drugs; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase 2 Inhibitors